Juvenile absence epilepsy

3 trials MedDRA PT
3 Registered trials
0 Recruiting
2 Unique sponsors
1 Unique IMPs
3 Commercial trials
Drug classes (ATC)
— ATC code not specified 3
Mechanism of action (INN-stem analysis)
Unknown / small molecule 1 substance
Phase III: 1 Phase II/III: 1 Phase I (Other): 1

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase III

1 trial
  • UCB Biopharma Commercial
    BRIVARACETAM
    2023-508095-11-00 4 countries 2024 n=31
    Ended

Phase II/III

1 trial
  • UCB Biopharma Commercial
    BRIVARACETAM
    2023-510428-55-00 4 countries 2022 n=107
    Ended

Phase I (Other)

1 trial
  • Saniona A/S Commercial
    IMP not specified
    2024-514514-12-00 1 country 2025 n=50
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
UCB Biopharma Commercial 2 Phase II/III, Phase III 0
Saniona A/S Commercial 1 Phase I (Other) 0
New trials by year
2022
1
2024
1
2025
1
← All indication landscapes